IL-1 family cytokines in cancer immunity - A matter of life and death

Biological Chemistry

Volumn 397, Issue 11, 2016, Pages 1125-1134

  Mora, Javier ^a,b   Weigert, Andreas ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSIDAD DE COSTA RICA   (Costa Rica)

Author keywords

cancer; cell death; cytokines; inflammation

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 33; INTERLEUKIN 36; INTERLEUKIN 37; INTERLEUKIN 38; UNCLASSIFIED DRUG;

CELL DEATH; HUMAN; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR IMMUNITY; ANIMAL; BIOSYNTHESIS; IMMUNOLOGY; METABOLISM; NEOPLASM; PATHOLOGY;

ANIMALS; CELL DEATH; HUMANS; INTERLEUKIN-1; NEOPLASMS;

EID: 84993983987     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/hsz-2016-0215     Document Type: Review

References (52)

1. Afonina, I.S., Muller, C., Martin, S.J., and Beyaert, R. (2015). Proteolytic processing of interleukin-1 family cytokines: variations on a common theme. Immunity 42, 991-1004
2. Akita, K., Ohtsuki, T., Nukada, Y., Tanimoto, T., Namba, M., Okura, T., Takakura-Yamamoto, R., Torigoe, K., Gu, Y., Su, MS., et al. (1997). Involvement of caspase-1 and caspase-3 in the production and processing of mature human interleukin in monocytic THP.1 cells. J. Biol. Chem. 272, 26595-26603
3. Bailey, S.R., Nelson, M.H., Himes, R.A., Li, Z., Mehrotra, S., and Paulos, C.M. (2014). Th17 cells in cancer: the ultimate identity crisis. Front. Immunol. 5, 276
4. Bensen, J.T., Dawson, P.A., Mychaleckyj, J.C., and Bowden, D.W. (2001). Identification of a novel human cytokine gene in the interleukin gene cluster on chromosome 2q12-14. J. Interferon. Cytokine Res. 21, 899-904
5. Bergis, D., Kassis, V., and Radeke, H.H. (2016). High plasma sST2 levels in gastric cancer and their association with metastatic disease. Cancer Biomark. 16, 117-125
6. Bergis, D., Kassis, V., Ranglack, A., Koeberle, V., Piiper, A., Kronenberger, B., Zeuzem, S., Waidmann, O., and Radeke, H.H. (2013). High serum levels of the interleukin-33 receptor soluble ST2 as a negative prognostic factor in hepatocellular carcinoma. Transl. Oncol. 6, 311-318
7. Dinarello, C.A., Nold-Petry, C., Nold, M., Fujita, M., Li, S., Kim, S., and Bufler, P. (2016). Suppression of innate inflammation and immunity by interleukin-37. Eur. J. Immunol. 46, 1067-1081
8. Dupaul-Chicoine, J., Arabzadeh, A., Dagenais, M., Douglas, T., Champagne, C., Morizot, A., Rodrigue-Gervais, I.G., Breton, V., Colpitts, S.L., Beauchemin, N., et al. (2015). The Nlrp3 inflammasome suppresses colorectal cancer metastatic growth in the liver by promoting natural killer cell tumoricidal activity. Immunity 43, 751-763
9. Eder, C. (2009). Mechanisms of interleukin-1beta release. Immunobiology 214, 543-553
10. Fabbi, M., Carbotti, G., and Ferrini, S. (2015). Context-dependent role of IL-18 in cancer biology and counter-regulation by IL-18BP. J. Leukoc. Biol. 97, 665-675
11. Gao, W., Kumar, S., Lotze, M.T., Hanning, C., Robbins, P.D., and Gambotto, A. (2003). Innate immunity mediated by the cytokine IL-1 homologue 4 (IL-1H4/IL-1F7) induces IL-12-dependent adaptive and profound antitumor immunity. J. Immunol. 170, 107-113
12. Gao, K., Li, X., Zhang, L., Bai, L., Dong, W., Gao, K., Shi, G., Xia, X., Wu, L., and Zhang, L. (2013). Transgenic expression of IL-33 activates CD8+ T cells and NK cells and inhibits tumor growth and metastasis in mice. Cancer Lett. 335, 463-471
13. Gao, X., Wang, X., Yang, Q., Zhao, X., Wen, W., Li, G., Lu, J., Qin, W., Qi, Y., Xie, F., et al. (2015). Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells. J. Immunol. 194, 438-445
14. Garlanda, C., Dinarello, C.A., and Mantovani, A. (2013). The interleukin-family: back to the future. Immunity 39, 1003-1018
15. Ge, G., Wang, A., Yang, J., Chen, Y., Yang, J., Li, Y., and Xue, Y. (2016). Interleukin-37 suppresses tumor growth through inhibition of angiogenesis in non-small cell lung cancer. J. Exp. Clin. Cancer Res. 35, 13
16. Ishikawa, K., Yagi-Nakanishi, S., Nakanishi, Y., Kondo, S., Tsuji, A., Endo, K., Wakisaka, N., Murono, S., and Yoshizaki, T. (2014). Expression of interleukin-33 is correlated with poor prognosis of patients with squamous cell carcinoma of the tongue. Auris Nasus Larynx 41, 552-557
17. Jiang, Y., Wang, Y., Liang, L., Gao, Y., Chen, J., Sun, Y., Cheng, Y., and Xu, Y. (2015). IL-37 mediates the antitumor activity in renal cell carcinoma. Med. Oncol. 32, 250
18. Jovanovic, I.P., Pejnovic, N.N., Radosavljevic, G.D., Pantic, J.M., Milovanovic, M.Z., Arsenijevic, N.N., and Lukic, M.L. (2014). Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. Int. J. Cancer 134, 1669-1682
19. Keller, M., Ruegg, A., Werner, S., and Beer, H.D. (2008). Active caspase-1 is a regulator of unconventional protein secretion. Cell 132, 818-831
20. Khan, J.A., Brint, E.K., O Neill, L.A., and Tong, L. (2004). Crystal structure of the Toll/interleukin-1 receptor domain of human IL-1RAPL. J. Biol. Chem. 279, 31664-31670
21. Komai-Koma, M., Wang, E., Kurowska-Stolarska, M., Li, D., McSharry, C., and Xu, D. (2016). Interleukin-33 promoting Th1 lymphocyte differentiation dependents on IL-12.Immunobiology 221, 412-417
22. Kuraishy, A., Karin, M., and Grivennikov, S.I. (2011). Tumor promotion via injury-and death-induced inflammation. Immunity 35, 467-477
23. Lauber, K., Ernst, A., Orth, M., Herrmann, M., and Belka, C. (2012). Dying cell clearance and its impact on the outcome of tumor radiotherapy. Front. Oncol. 2, 116
24. Liang, Y., Jie, Z., Hou, L., Yi, P., Wang, W., Kwota, Z., Salvato, M., de Waal Malefyt, R., Soong, L., and Sun, J. (2015). IL-33 promotes innate IFN-gamma production and modulates dendritic cell response in LCMV-induced hepatitis in mice. Eur. J. Immunol. 45, 3052-3063
25. Lin, H., Ho, A.S., Haley-Vicente, D., Zhang, J., Bernal-Fussell, J., Pace, A.M., Hansen, D., Schweighofer, K., Mize, N.K., and Ford, J.E. (2001). Cloning and characterization of IL-1HY2, a novel interleukin-1 family member. J. Biol. Chem. 276, 20597-20602
26. Liu, J., Shen, J.X., Hu, J.L., Huang, W.H., and Zhang, G.J. (2014a). Significance of interleukin-33 and its related cytokines in patients with breast cancers. Front. Immunol. 5, 141
27. Liu, X., Zhu, L., Lu, X., Bian, H., Wu, X., Yang, W., and Qin, Q. (2014b). IL-33/ST2 pathway contributes to metastasis of human colorectal cancer. Biochem. Biophys Res. Commun. 453, 486-492
28. Lu, B., Yang, M., and Wang, Q. (2016). Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapy. J. Mol. Med. (Berl) 94, 535-543
29. Ma, Y., Aymeric, L., Locher, C., Mattarollo, S.R., Delahaye, N.F., Pereira, P., Boucontet, L., Apetoh, L., Ghiringhelli, F., Casares, N., et al. (2011). Contribution of IL-17-producing ãä T cells to the efficacy of anticancer chemotherapy. J. Exp. Med. 208, 491-503
30. Ma, Z., Li, W., Yoshiya, S., Xu, Y., Hata, M., El-Darawish, Y., Markova, T., Yamanishi, K., Yamanishi, H., Tahara, H., et al. (2016). Augmentation of immune checkpoint cancer immunotherapy with IL18. Clin. Cancer Res. 22, 2969-2980
31. McNamee, E.N., Masterson, J.C., Jedlicka, P., McManus, M., Grenz, A., Collins, C.B., Nold, M.F., Nold-Petry, C., Bufler, P., Dinarello, C.A., et al. (2011). Interleukin 37 expression protects mice from colitis. Proc. Natl. Acad. Sci. USA 108, 16711-16716
32. Mora, J., Schlemmer, A., Wittig, I., Richter, F., Putyrski, M., Frank, A.C., Han, Y., Jung, M., Ernst, A., Weigert, A., et al. (2016). Interleukin-38 is released from apoptotic cells to limit inflammatory macrophage responses. J. Mol. Cell Biol., Epub ahead of print
33. Netea, M.G., van de Veerdonk, F.L., van der Meer, J.W., Dinarello, C.A., and Joosten, L.A. (2015). Inflammasome-independent regulation of IL-1-family cytokines. Annu. Rev. Immunol. 33, 49-77
34. Pan, Q.Z., Pan, K., Zhao, J.J., Chen, J.G., Li, J.J., Lv, L., Wang, D.D., Zheng, H.X., Jiang, S.S., Zhang, X.F., et al. (2013). Decreased expression of interleukin-36alpha correlates with poor prognosis in hepatocellular carcinoma. Cancer Immunol. Immunother. 62, 1675-1685
35. Pavlowsky, A., Zanchi, A., Pallotto, M., Giustetto, M., Chelly, J., Sala, C., and Billuart, P. (2010). Neuronal JNK pathway activation by IL-1 is mediated through IL1RAPL1, a protein required for development of cognitive functions. Commun. Integr. Biol. 3, 245-247
36. Tong, X., Barbour, M., Hou, K., Gao, C., Cao, S., Zheng, J., Zhao, Y., Mu, R., and Jiang, H.R. (2016). Interleukin-33 predicts poor prognosis and promotes ovarian cancer cell growth and metastasis through regulating ERK and JNK signaling pathways. Mol. Oncol. 10, 113-125
37. Trinchieri, G. (2012). Cancer and inflammation: an old intuition with rapidly evolving new concepts. Annu. Rev. Immunol. 30, 677-706
38. Tsuda, H., Komine, M., Karakawa, M., Etoh, T., Tominaga, S., and Ohtsuki, M. (2012). Novel splice variants of IL-33: differential expression in normal and transformed cells. J. Invest. Dermatol. 132, 2661-2664
39. van de Veerdonk, F.L., Stoeckman, A.K., Wu, G., Boeckermann, A.N., Azam, T., Netea, M.G., Joosten, L.A., van der Meer, J.W., Hao, R., Kalabokis, V., et al. (2012). IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist. Proc. Natl. Acad. Sci. USA 109, 3001-3005
40. Villarreal, D.O. and Weiner, D.B. (2014). Interleukin 33: a switchhitting cytokine. Curr. Opin. Immunol. 28, 102-106
41. Voronov, E., Dotan, S., Krelin, Y., Song, X., Elkabets, M., Carmi, Y., Rider, P., Idan, C., Romzova, M., Kaplanov, I., et al. (2013). Unique versus redundant functions of IL-1á and IL-1â in the tumor microenvironment. Front. Immunol. 4, 177
42. Wang, Z.S., Cong, Z.J., Luo, Y., Mu, Y.F., Qin, S.L., Zhong, M., and Chen, J.J. (2014). Decreased expression of interleukin-36á predicts poor prognosis in colorectal cancer patients. Int. J. Clin. Exp. Pathol. 7, 8077-8081
43. Wang, S., An, W., Yao, Y., Chen, R., Zheng, X., Yang, W., Zhao, Y., Hu, X., Jiang, E., Bie, Y., et al. (2015a). Interleukin 37 expression inhibits STAT3 to suppress the proliferation and invasion of human cervical cancer cells. J. Cancer 6, 962-969
44. Wang, X., Zhao, X., Feng, C., Weinstein, A., Xia, R., Wen, W., Lv, Q., Zuo, S., Tang, P., Yang, X., et al. (2015b). IL-36ã transforms the tumor microenvironment and promotes type 1 lymphocytemediated antitumor immune responses. Cancer Cell 28, 296-306
45. Willems, J.J., Arnold, B.P., and Gregory, C.D. (2014). Sinister selfsacrifice: the contribution of apoptosis to malignancy. Front. Immunol. 5, 299
46. Xu, D., Chan, W.L., Leung, B.P., Huang, F., Wheeler, R., Piedrafita, D., Robinson, J.H., and Liew, F.Y. (1998). Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J. Exp. Med. 187, 787-794
47. Yang, Q., Li, G., Zhu, Y., Liu, L., Chen, E., Turnquist, H., Zhang, X., Finn, O.J., Chen, X., and Lu, B. (2011). IL-33 synergizes with TCR and IL-12 signaling to promote the effector function of CD8+ T cells. Eur. J. Immunol. 41, 3351-3360
48. Yang, Z.P., Ling, D.Y., Xie, Y.H., Wu, W.X., Li, J.R., Jiang, J., Zheng, J.L., Fan, Y.H., and Zhang, Y. (2015). The association of serum IL-33 and sST2 with breast cancer. Dis. Markers 2015, 516895
49. Yu, X.X., Hu, Z., Shen, X., Dong, L.Y., Zhou, W.Z., and Hu, W.H. (2015). IL-33 promotes gastric cancer cell invasion and migration via ST2-ERK1/2 pathway. Dig. Dis. Sci. 60, 1265-1272
50. Zhao, J.J., Pan, Q.Z., Pan, K., Weng, D.S., Wang, Q.J., Li, J.J., Lv, L., Wang, D.D., Zheng, H.X., Jiang, S.S., et al. (2014). Interleukin-mediates the antitumor activity in hepatocellular carcinoma: role for CD57+ NK cells. Sci. Rep. 4, 5177
51. Zitvogel, L., Kepp, O., and Kroemer, G. (2011). Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat. Rev. Clin. Oncol. 8, 151-160
52. Zitvogel, L., Kepp, O., Galluzzi, L., and Kroemer, G. (2012). Inflammasomes in carcinogenesis and anticancer immune responses. Nat. Immunol. 13, 343-351